Project Details
| Status | Active |
|---|---|
| Effective start/end date | 1/6/21 → 1/6/24 |
Funding
- Seattle Genetics, Inc. (Prot #SGNLVA-005)
Prot #SGNLVA-005: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
- Mulcahy, Mary Frances (PD/PI)
Project: Research project